Sean Nolan gath­ers AveX­is alum­ni to launch an­oth­er biotech. Is it an­oth­er race-to-IPO?

The old AveX­is crew is launch­ing an­oth­er com­pa­ny. And they may once again look to cash in quick.

Armed with patents and a steady stream of cash from Deer­field Man­age­ment, Sean Nolan and five ex-AveX­is ex­ec­u­tives have launched Jaguar Gene Ther­a­py to de­vel­op AAV9 gene ther­a­pies for a small con­stel­la­tion of dis­parate dis­or­ders, from autism to di­a­betes. Jaguar re­mains over a year from the clin­ic, but CEO Joe Nolan hint­ed they could look to fol­low a pace set by Ta­sy­ha, the biotech Sean Nolan and oth­er AveX­is alum­ni launched last year and took from Se­ries A to IPO in less than 6 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER